Medicure Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Albert David Friesen
- Full Time Employees
- 23
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2-1250 Waverley Street Winnipeg MB Canada R3T 6C6
- IPO Date
- Feb 19, 2004
- CIK
- 0001133519
- Website
- medicure.com
- Similar Companies
- Business
- Medicure Inc. (TSXV:MPH; OTC:MCUJF) is a pharmaceutical company focused on the development and commercialization of cardiovascular therapeutics and healthcare products for the U.S. market. The company markets and distributes AGGRASTAT (tirofiban hydrochloride) injection, a glycoprotein IIb/IIIa inhibitor used in cardiac catheterization labs to reduce thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome; ZYPITAMAG (pitavastatin) tablets, an HMG-CoA reductase inhibitor statin approved by the U.S. Food and Drug Administration in 2017 for lowering cholesterol; sodium nitroprusside injection, an acute care cardiovascular drug; and BRENZAVVY, offered through its integrated e-commerce platform for direct online ordering and home delivery to patients and providers. Medicure operates Marley Drug Inc., a direct-to-consumer pharmacy servicing all 50 U.S. states, Washington D.C., and Puerto Rico, with a commitment to improving medication access and adherence; it also pursues its pipeline of pyridoxal 5'-phosphate analogues (P5P Analogues). Founded in 1997 and headquartered in Winnipeg, Manitoba, Canada, the company conducts its U.S. operations through wholly-owned subsidiaries including Medicure Pharma Inc., Medicure USA Inc., and Medicure International Inc. (Barbados), targeting physicians, healthcare professionals, hospitals, and patients in the cardiovascular and specialty pharmaceutical segments. In recent developments, Medicure expanded its pharmacy business through the acquisition of Gateway Medical Pharmacy and the closing of its purchase of West Olympia Pharmacy Inc. in June 2025 for USD $975,000, adding approximately $10 million in projected annual net revenue to accelerate ZYPITAMAG and BRENZAVVY sales while enhancing patient access; the company also signed an asset purchase agreement in August 2025 with CanAm Bioresearch Inc. to acquire intellectual property supporting its growth strategy.
Company News
Medicure (OTCMKTS:MCUJF) Share Price Breaks Above 50-Day Moving Average – What’s Next?
Medicure (OTCMKTS:MCUJF) Shares Break Above 50-Day Moving Average – Time to Sell?
Medicure Announces Grant of Stock Options
Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial
Medicure (OTCMKTS:MCUJF) Shares Cross Above 50-Day Moving Average – Should You Sell?
Medicure Presents MEND-PNPO Phase 3 Study Design and Baseline Data at the 16th European Epilepsy Congress
Medicure Inc. (MPH:CA) Q2 2026 Earnings Call Prepared Remarks Transcript
Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call
Comparing Medicure (OTCMKTS:MCUJF) & Takeda Pharmaceutical (NYSE:TAK)
Medicure Announces CFO Change
Medicure Inc. (MPH:CA) Q1 2026 Earnings Call Prepared Remarks Transcript
Medicure Announces AGM Results and Appointment of New Director
Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
Medicure Inc. (MPH:CA) Q4 2025 Earnings Call Prepared Remarks Transcript
Medicure (OTCMKTS:MCUJF) and Wellgistics Health (NASDAQ:WGRX) Head to Head Analysis
Medicure Announces Resignation of President and Chief Operating Officer
Medicure (OTCMKTS:MCUJF) Share Price Crosses Above 50 Day Moving Average – Here’s Why
Medicure Inc. (MPH:CA) Q3 2025 Earnings Call Transcript
Medicure Reports Financial Results for Quarter Ended September 30, 2025
Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025